The Process of Developing a Disease Activity Index in Microscopic Colitis

Area of Science:

• Gastroenterology
• Clinical Outcome Assessment

Background:

• Microscopic colitis (MC) requires patient-reported outcome measures (PROMs) to assess disease impact on daily life.
• Current PROMs may not fully meet regulatory standards for assessing MC disease activity.

Purpose of the Study:

• Develop a PROM for microscopic colitis disease activity assessment.
• Ensure the developed PROM aligns with Food and Drug Administration (FDA) guidelines.

Main Methods:

• The European Microscopic Colitis Activity Index (E-MCAI) was developed through expert and patient consensus.
• Content validity was established using the Content Validity Index with 14 experts and 79 patients.
• Cognitive interviews and a pilot survey refined the E-MCAI's questions and usability.

Main Results:

• Seven key symptoms of active MC demonstrated content validity: stool consistency, frequency, nocturnal stools, urgency, incomplete evacuation, leakage, and abdominal pain.
• The final E-MCAI comprises six questions, reflecting core aspects of microscopic colitis activity.
• The development process adhered to FDA-recommended methodologies.

Conclusions:

• The E-MCAI is a newly developed PROM for microscopic colitis.
• Initial evaluations indicate good content validity, meeting FDA development standards.
• Further studies are planned to establish construct validity, reliability, and responsiveness.